Reunion Neuroscience: Funding, Investors & Team (Oct 2026)
Reunion Neuroscience is a pharmaceutical company in the clinical stage that is working on creating treatments for mental health conditions that are often neglected. Their main product, RE104, is a unique psychedelic compound that works on serotonin receptors and is being studied as a potential quick-acting and long-lasting antidepressant for patients with postpartum depression and other mental health issues. Additionally, Reunion is also working on the RE200 series, which consists of compounds that have the potential for more targeted serotonin receptor activity and less psychoactive effects, making them suitable for use in more long-term treatment plans and for a wider range of conditions.
Reunion Neuroscience has raised $236M across 2 funding rounds on record, the most recent a Series A of $133M announced in Sep 2025.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Reunion Neuroscience Company Profile and Key Stats
Latest funding round on record: Sep 2025.
Reunion Neuroscience Funding Rounds
Reunion Neuroscience raised $103M in a Series A announced in May 2024.
1.3 years later, a Series A of $133M was announced in Sep 2025.
Reunion Neuroscience Founders and Leadership Team
Contact details for the Reunion Neuroscience team: 1 of 1 has an email address on file.
Start 14-day free trial →Reunion Neuroscience Funding Compared to Other Biotechnology Startups
Reunion Neuroscience's latest round of $133M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Reunion Neuroscience in Biotechnology and Toronto
Companies Similar to Reunion Neuroscience
Tydra Labs is a biotechnology company that transforms crustacean shell waste into chitin and bio-products.
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…
Reunion Neuroscience Funding FAQs
What does Reunion Neuroscience do?
Reunion Neuroscience is a pharmaceutical company in the clinical stage that is working on creating treatments for mental health conditions that are often neglected. Their main product, RE104, is a unique psychedelic compound that works on serotonin receptors and is being studied as a potential quick-acting and long-lasting antidepressant for patients with postpartum depression and other mental health issues. Additionally, Reunion is also working on the RE200 series, which consists of compounds that have the potential for more targeted serotonin receptor activity and less psychoactive effects, making them suitable for use in more long-term treatment plans and for a wider range of conditions.
How much funding has Reunion Neuroscience raised?
Reunion Neuroscience has raised $236M across 2 rounds on record. The most recent is a Series A of $133M announced in Sep 2025.
When did Reunion Neuroscience last raise funding?
Reunion Neuroscience's most recent funding round on record is a Series A of $133M, announced in Sep 2025.
Who founded Reunion Neuroscience?
FundedIQ lists Greg Mayes (Founder) at Reunion Neuroscience.
Where is Reunion Neuroscience headquartered?
Reunion Neuroscience is based in Toronto, Ontario, Canada.
How many employees does Reunion Neuroscience have?
Reunion Neuroscience is in the 11-50 employee band.
How does Reunion Neuroscience's funding compare to other Biotechnology startups?
Reunion Neuroscience's latest round of $133M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Reunion Neuroscience Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Reunion Neuroscience is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.